Epidermolysis Bullosa-Pipeline Review, H1 2017

Epidermolysis Bullosa-Pipeline Review, H1 2017


  • Products Id :- GMDHC9232IDB
  • |
  • Pages: 101
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Epidermolysis Bullosa-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa-Pipeline Review, H1 2017, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8, 2, 9 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).

The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Epidermolysis Bullosa-Overview

Epidermolysis Bullosa-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Epidermolysis Bullosa-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Epidermolysis Bullosa-Companies Involved in Therapeutics Development

Abeona Therapeutics Inc

Almirall SA

Amryt Pharma plc

Anterogen Co Ltd

Berg LLC

CSL Ltd

Exicure Inc

Fibrocell Science Inc

GlaxoSmithKline Plc

Immusoft Corp

InMed Pharmaceuticals Inc

Karus Therapeutics Ltd

Mesoblast Ltd

ProQR Therapeutics NV

RegeneRx Biopharmaceuticals Inc

Scioderm Inc

Stratatech Corp

TransDerm Inc

WAVE Life Sciences Ltd

Epidermolysis Bullosa-Drug Profiles

AC-203-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADP-31415-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

allantoin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALLO-ASC-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide 1 to Inhibit Keratin for Epidermolysis Bullosa Simplex-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide 2 to Inhibit Keratin for Epidermolysis Bullosa Simplex-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Epidermolysis Bullosa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

birch bark extract-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Dermatology and Immunology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Epidermolysis Bullosa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCX-007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Epidermolysis Bullosa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Epidermolysis Bullosa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICX-RHY-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INM-750-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KA-1463-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-230-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QR-313-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QRX-323-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remestemcel-L-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGN-137-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TXA-127-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ubidecarenone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epidermolysis Bullosa-Dormant Projects

Epidermolysis Bullosa-Discontinued Products

Epidermolysis Bullosa-Product Development Milestones

Featured News & Press Releases

May 02, 2017: Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference

Apr 25, 2017: Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting

Apr 24, 2017: Amryt Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial for AP101 in EB

Apr 03, 2017: Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study

Mar 28, 2017: Amryt Pharma: Phase 3 Clinical Trial for AP101 in EB

Mar 08, 2017: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

Mar 06, 2017: Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex

Mar 06, 2017: Amryt Pharma Announces AP101 trial discussions completed with FDA & EMA

Feb 27, 2017: RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.

Feb 23, 2017: Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa

Feb 07, 2017: Amryt Pharma: Grant of patent in Japan for lead drug candidate, AP101 (Episalvan) for Treatment of Epidermolysis Bullosa

Jan 18, 2017: Tarix Orphan Receives Rare Pediatric Disease Designation for TXA127 for Recessive Dystrophic Epidermolysis Bullosa

Jan 05, 2017: Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

Dec 02, 2016: Amryt Pharma: EUR20m facility agreed with European Investment Bank

Nov 05, 2016: Abeona Therapeutics Honored with Partner in Progress Award from DEBRA of America

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Epidermolysis Bullosa, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Epidermolysis Bullosa, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Epidermolysis Bullosa-Pipeline by Abeona Therapeutics Inc, H1 2017

Epidermolysis Bullosa-Pipeline by Almirall SA, H1 2017

Epidermolysis Bullosa-Pipeline by Amryt Pharma plc, H1 2017

Epidermolysis Bullosa-Pipeline by Anterogen Co Ltd, H1 2017

Epidermolysis Bullosa-Pipeline by Berg LLC, H1 2017

Epidermolysis Bullosa-Pipeline by CSL Ltd, H1 2017

Epidermolysis Bullosa-Pipeline by Exicure Inc, H1 2017

Epidermolysis Bullosa-Pipeline by Fibrocell Science Inc, H1 2017

Epidermolysis Bullosa-Pipeline by GlaxoSmithKline Plc, H1 2017

Epidermolysis Bullosa-Pipeline by Immusoft Corp, H1 2017

Epidermolysis Bullosa-Pipeline by InMed Pharmaceuticals Inc, H1 2017

Epidermolysis Bullosa-Pipeline by Karus Therapeutics Ltd, H1 2017

Epidermolysis Bullosa-Pipeline by Mesoblast Ltd, H1 2017

Epidermolysis Bullosa-Pipeline by ProQR Therapeutics NV, H1 2017

Epidermolysis Bullosa-Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017

Epidermolysis Bullosa-Pipeline by Scioderm Inc, H1 2017

Epidermolysis Bullosa-Pipeline by Stratatech Corp, H1 2017

Epidermolysis Bullosa-Pipeline by TransDerm Inc, H1 2017

Epidermolysis Bullosa-Pipeline by WAVE Life Sciences Ltd, H1 2017

Epidermolysis Bullosa-Dormant Projects, H1 2017

Epidermolysis Bullosa-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abeona Therapeutics Inc, Almirall SA, Amryt Pharma plc, Anterogen Co Ltd, Berg LLC, CSL Ltd, Exicure Inc, Fibrocell Science Inc, GlaxoSmithKline Plc, Immusoft Corp, InMed Pharmaceuticals Inc, Karus Therapeutics Ltd, Mesoblast Ltd, ProQR Therapeutics NV, RegeneRx Biopharmaceuticals Inc, Scioderm Inc, Stratatech Corp, TransDerm Inc, WAVE Life Sciences Ltd

select a license

Single User License
USD 2000 INR 129560
Site License
USD 4000 INR 259120
Corporate User License
USD 6000 INR 388680

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com